IFNB1 and chronic obstructive pulmonary disease: In a recent clinical study by Synairgen, IFN-β treatment of chronic obstruction pulmonary disease patients aged 60 or higher showed very little adverse effects, substantiating that using IFN-β in high dosages might provide a safe prophylactic solution for preventing a viral respiratory infection.